Intravesical agent shows some promise in treating IC
Whistler, British Columbia, Canada-Intravesical hyaluronic acid (Cystistat) appears to be a simple, quick therapy for reducing pain, frequency, and nocturia in patients with interstitial cystitis, according to Austrian and Canadian researchers. The agent may also improve radiation-induced cystitis and reduce bacterial cystitis recurrences in patients with recurrent urinary tract infections, said Marc Riviere, MD, senior vice president at Belleville, Ontario-based Bioniche Life Sciences Inc., who presented a series of pilot studies at the Canadian Urological Association annual meeting.
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.